Anders Olsen and colleagues explore patenting on insulin products by the Federal Drug Agency (FDA) and the impact on market exclusivity and drug prices.
This Viewpoint discusses 3 bills introduced recently in Congress that focus on patent eligibility, fraud, and quality and that have major implications for clini